{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:35:38Z","timestamp":1790688938818,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW010060"],"award-info":[{"award-number":["D43TW010060"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F30MH111370"],"award-info":[{"award-number":["F30MH111370"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HD080485"],"award-info":[{"award-number":["R01HD080485"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HD080485"],"award-info":[{"award-number":["R01HD080485"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HD080485"],"award-info":[{"award-number":["R01HD080485"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HD080485"],"award-info":[{"award-number":["R01HD080485"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HD080485"],"award-info":[{"award-number":["R01HD080485"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW010060"],"award-info":[{"award-number":["D43TW010060"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HD080485"],"award-info":[{"award-number":["R01HD080485"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW010060"],"award-info":[{"award-number":["D43TW010060"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Antiretroviral therapy (ART) is very effective in preventing vertical transmission of HIV but some women on ART experience different virologic, immunologic, and safety profiles. While most pregnant women are closely monitored for short-term effects of ART during pregnancy, few women receive similar attention beyond pregnancy. We aimed to assess retention in care and clinical and laboratory-confirmed outcomes over 3 years after starting ART under Malawi\u2019s Option B\u2009+\u2009program.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a prospective cohort study of pregnant women newly diagnosed with HIV who started tenofovir disoproxil fumarate\/emtricitabine\/efavirenz (TDF\/3TC\/EFV) for the first time at Bwaila Hospital in Lilongwe, Malawi between May 2015 and June 2016. Participants were followed for 3 years. We summarized demographic characteristics, pregnancy outcomes, and clinical and laboratory adverse events findings using proportions. Log-binomial regression models were used to estimate the overall risk ratios (RR) and the corresponding 95% confidence interval (CI) for the association between index pregnancy (i.e. index pregnancy vs. subsequent pregnancy) and preterm birth, and index pregnancy and low birthweight.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 299 pregnant women who were enrolled in the study, 255 (85.3%) were retained in care. There were 340 total pregnancies with known outcomes during the 36-month study period, 280 index pregnancies, and 60 subsequent pregnancies. The risks of delivering preterm (9.5% for index pregnancy and13.5% for subsequent pregnancy: RR\u2009=\u20090.70; 95% CI: 0.32\u20131.54), or low birth weight infant (9.8% for index pregnancy and 4.2% for subsequent pregnancy: RR\u2009=\u20092.36; 95% CI: 0.58\u20139.66) were similar between index and subsequent pregnancies. Perinatally acquired HIV was diagnosed in 6 (2.3%) infants from index pregnancies and none from subsequent pregnancies. A total of 50 (16.7%) women had at least one new clinical adverse event and 109 (36.5%) women had at least one incident abnormal laboratory finding. Twenty-two (7.3%) women switched to second line ART: of these 64.7% (8\/17) had suppressed viral load and 54.9% (6\/17) had undetectable viral load at 36 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Most of the women who started TDF\/3TC\/EFV were retained in care and few infants were diagnosed with perinatally acquired HIV. Despite switching, women who switched to second line therapy continued to have higher viral loads suggesting that additional factors beyond TDF\/3TC\/EFV failure may have contributed to the switch. Ongoing support during the postpartum period is necessary to ensure retention in care and prevention of vertical transmission.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-023-00523-1","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T09:02:23Z","timestamp":1686560543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy \u2013 Malawi option B+"],"prefix":"10.1186","volume":"20","author":[{"given":"Maganizo B.","family":"Chagomerana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryna J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany L.","family":"DiPrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaphil","family":"Wallie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalitso","family":"Maliwichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Wesevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob N.","family":"Phulusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiza","family":"Kumwenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Jumbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina C.","family":"Hosseinipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"523_CR1","volume-title":"Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendation for a Public Health Approach","author":"WHO","year":"2013","unstructured":"WHO. Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendation for a Public Health Approach. Geneva, Switzerland: WHO Press; 2013."},{"key":"523_CR2","unstructured":"UNAIDS. UNAIDS Data 2020 [Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2020_aids-data-book_en.pdf."},{"key":"523_CR3","volume-title":"Global guidance on criteria and processes for validation: elimination of Mother-to-child transmission of HIV and Syphilis","author":"WHO","year":"2017","unstructured":"WHO. Global guidance on criteria and processes for validation: elimination of Mother-to-child transmission of HIV and Syphilis. Geneva, Switzerland: WHO; 2017."},{"issue":"3","key":"523_CR4","doi-asserted-by":"publisher","first-page":"F11","DOI":"10.1097\/QAD.0b013e328335749d","volume":"24","author":"JW Hargrove","year":"2010","unstructured":"Hargrove JW, Humphrey JH. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS. 2010;24(3):F11\u20134.","journal-title":"AIDS"},{"issue":"5","key":"523_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/COH.0b013e328363a8f2","volume":"8","author":"S Ahmed","year":"2013","unstructured":"Ahmed S, Kim MH, Abrams EJ. Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: a review of the evidence for the option B + approach. Curr Opin HIV AIDS. 2013;8(5):474\u201389.","journal-title":"Curr Opin HIV AIDS"},{"issue":"9672","key":"523_CR6","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(09)60612-7","volume":"373","author":"JA Sterne","year":"2009","unstructured":"Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352\u201363.","journal-title":"Lancet"},{"issue":"6","key":"523_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493\u2013505.","journal-title":"N Engl J Med"},{"issue":"9","key":"523_CR8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1600693","volume":"375","author":"MS Cohen","year":"2016","unstructured":"Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the Prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"523_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1310\/hct0805-328","volume":"8","author":"J Arrizabalaga","year":"2007","unstructured":"Arrizabalaga J, Arazo P, Aguirrebengoa K, Garc\u00eda-Palomo D, Chocarro A, Labarga P, et al. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART. HIV Clin Trial. 2007;8(5):328\u201336.","journal-title":"HIV Clin Trial"},{"key":"523_CR10","unstructured":"WHO. Consolidated guidelines on the useof antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, second edition. Geneva, Switzerland: WHO Press; 2016."},{"issue":"4","key":"523_CR11","doi-asserted-by":"publisher","first-page":"e0195033","DOI":"10.1371\/journal.pone.0195033","volume":"13","author":"MB Chagomerana","year":"2018","unstructured":"Chagomerana MB, Miller WC, Tang JH, Hoffman IF, Mthiko BC, Phulusa J, et al. Optimizing prevention of HIV mother to child transmission: duration of antiretroviral therapy and viral suppression at delivery among pregnant malawian women. PLoS ONE. 2018;13(4):e0195033.","journal-title":"PLoS ONE"},{"issue":"Suppl 2","key":"523_CR12","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1097\/QAI.0000000000001368","volume":"75","author":"M Hosseinipour","year":"2017","unstructured":"Hosseinipour M, Nelson JAE, Trapence C, Rutstein SE, Kasende F, Kayoyo V, et al. Viral suppression and HIV Drug Resistance at 6 months among women in Malawi\u2019s option B+ program: results from the PURE Malawi Study. J Acquir Immune Defic Syndr. 2017;75(Suppl 2):S149\u2013S55.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"523_CR13","first-page":"1221","volume-title":"Safety and efficacy of option B + ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir\/lamivudine\/efavirenz","author":"BJ Harrington","year":"2019","unstructured":"Harrington BJ, DiPrete BL, Jumbe AN, Ngongondo M, Limarzi L, Wallie SD, et al. Safety and efficacy of option B + ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir\/lamivudine\/efavirenz. Volume 24. Tropical medicine & international health: TM & IH; 2019. pp. 1221\u20138. 10."},{"key":"523_CR14","volume-title":"Malawi Guidelines for Clinical Management of HIV in children and adults","author":"Republic of Malawi MoH","year":"2016","unstructured":"Republic of Malawi MoH. Malawi Guidelines for Clinical Management of HIV in children and adults. Lilongwe, Malawi: Ministry of Health; 2016."},{"key":"523_CR15","volume-title":"Malawi Guidelines for Clinical Management of HIV in children and adults","author":"Republic of Malawi MoH","year":"2018","unstructured":"Republic of Malawi MoH. Malawi Guidelines for Clinical Management of HIV in children and adults. Lilongwe, Malawi: Ministry of Health; 2018."},{"key":"523_CR16","volume-title":"Malawi Guidelines for Clinical Management of HIV in children and adults","author":"Republic of Malawi MoH","year":"2014","unstructured":"Republic of Malawi MoH. Malawi Guidelines for Clinical Management of HIV in children and adults. Lilongwe, Malawi: Ministry of Health; 2014."},{"key":"523_CR17","unstructured":"U.S. Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. 2017."},{"issue":"6","key":"523_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/hiv.12473","volume":"18","author":"M Floridia","year":"2017","unstructured":"Floridia M, Tamburrini E, Masuelli G, Martinelli P, Spinillo A, Liuzzi G, et al. Rate, correlates and outcomes of repeat pregnancy in HIV-infected women. HIV Med. 2017;18(6):440\u20133.","journal-title":"HIV Med"},{"key":"523_CR19","doi-asserted-by":"crossref","unstructured":"Bryant AS, Leighty RM, Shen X, Read JS, Brouwers P, Turpin DB et al. Predictors of repeat pregnancy among HIV-1-infected women. Journal of acquired immune deficiency syndromes (1999). 2007;44(1):87\u201392.","DOI":"10.1097\/01.qai.0000243116.14165.52"},{"issue":"6","key":"523_CR20","doi-asserted-by":"publisher","first-page":"e0131163","DOI":"10.1371\/journal.pone.0131163","volume":"10","author":"V Akelo","year":"2015","unstructured":"Akelo V, McLellan-Lemal E, Toledo L, Girde S, Borkowf CB, Ward L, et al. Determinants and experiences of repeat pregnancy among HIV-Positive kenyan Women\u2013A mixed-methods analysis. PLoS ONE. 2015;10(6):e0131163.","journal-title":"PLoS ONE"},{"issue":"10","key":"523_CR21","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1080\/09540121.2015.1050987","volume":"27","author":"R Kreitchmann","year":"2015","unstructured":"Kreitchmann R, Megazzini K, Melo VH, Fernandes Coelho D, Watts DH, Krauss M, et al. Repeat pregnancy in women with HIV infection in Latin America and the Caribbean. AIDS Care. 2015;27(10):1289\u201397.","journal-title":"AIDS Care"},{"key":"523_CR22","doi-asserted-by":"crossref","unstructured":"French CE, Cortina-Borja M, Thorne C, Tookey PA. Incidence, patterns, and predictors of repeat pregnancies among HIV-infected women in the United Kingdom and Ireland, 1990\u20132009. Journal of acquired immune deficiency syndromes (1999). 2012;59(3):287 \u2013 93.","DOI":"10.1097\/QAI.0b013e31823dbeac"},{"issue":"6","key":"523_CR23","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s10461-010-9788-7","volume":"15","author":"NG De La Cruz","year":"2011","unstructured":"De La Cruz NG, Davies SL, Stewart KE. Religion, relationships and reproduction: correlates of desire for a child among mothers living with HIV. AIDS Behav. 2011;15(6):1233\u201342.","journal-title":"AIDS Behav"},{"issue":"6","key":"523_CR24","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/ajcn\/73.6.1066","volume":"73","author":"H Friis","year":"2001","unstructured":"Friis H, Gomo E, Koestel P, Ndhlovu P, Nyazema N, Krarup H, et al. HIV and other predictors of serum folate, serum ferritin, and hemoglobin in pregnancy: a cross-sectional study in Zimbabwe. Am J Clin Nutr. 2001;73(6):1066\u201373.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"523_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1017\/S1368980008002401","volume":"12","author":"E McLean","year":"2009","unstructured":"McLean E, Cogswell M, Egli I, Wojdyla D, De Benoist B. Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993\u20132005. Public Health Nutr. 2009;12(4):444\u201354.","journal-title":"Public Health Nutr"},{"key":"523_CR26","unstructured":"Bank TW. Prevalence of anemia among pregnant women [Available from: https:\/\/data.worldbank.org\/indicator\/SH.PRG.ANEM."},{"issue":"Suppl 1","key":"523_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0020-7292(11)60005-2","volume":"115","author":"R Gangopadhyay","year":"2011","unstructured":"Gangopadhyay R, Karoshi M, Keith L. Anemia and pregnancy: a link to maternal chronic diseases. Int J Gynaecol Obstet. 2011;115(Suppl 1):11\u20135.","journal-title":"Int J Gynaecol Obstet"},{"key":"523_CR28","first-page":"f3443","volume":"346","author":"BA Haider","year":"2013","unstructured":"Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW. Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ (Clinical research ed). 2013;346:f3443.","journal-title":"BMJ (Clinical research ed)"},{"issue":"Suppl 7A","key":"523_CR29","doi-asserted-by":"publisher","first-page":"27S","DOI":"10.1016\/j.amjmed.2003.12.010","volume":"116","author":"PS Belperio","year":"2004","unstructured":"Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):27S\u201343S.","journal-title":"Am J Med"},{"key":"523_CR30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1186\/1471-2334-13-522","volume":"13","author":"BK Sartorius","year":"2013","unstructured":"Sartorius BK, Chersich MF, Mwaura M, Meda N, Temmerman M, Newell ML, et al. Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three african countries. BMC Infect Dis. 2013;13:522.","journal-title":"BMC Infect Dis"},{"issue":"13","key":"523_CR31","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1097\/QAD.0b013e3283493ed0","volume":"25","author":"MC Marazzi","year":"2011","unstructured":"Marazzi MC, Palombi L, Nielsen-Saines K, Haswell J, Zimba I, Magid NA, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS. 2011;25(13):1611\u20138.","journal-title":"AIDS"},{"issue":"9","key":"523_CR32","doi-asserted-by":"publisher","first-page":"e106103","DOI":"10.1371\/journal.pone.0106103","volume":"9","author":"V Nandlal","year":"2014","unstructured":"Nandlal V, Moodley D, Grobler A, Bagratee J, Maharaj NR, Richardson P. Anaemia in pregnancy is associated with advanced HIV disease. PLoS ONE. 2014;9(9):e106103.","journal-title":"PLoS ONE"},{"issue":"1","key":"523_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s12879-018-3397-x","volume":"18","author":"AM Delicio","year":"2018","unstructured":"Delicio AM, Lajos GJ, Amaral E, Lopes F, Cavichiolli F, Myioshi I, et al. Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study. BMC Infect Dis. 2018;18(1):485.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"523_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/QAD.0000000000000620","volume":"29","author":"S Huntington","year":"2015","unstructured":"Huntington S, Thorne C, Newell ML, Anderson J, Taylor GP, Pillay D, et al. Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. AIDS. 2015;29(7):801\u20139.","journal-title":"AIDS"},{"issue":"18","key":"523_CR35","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1097\/QAD.0b013e32832e34b1","volume":"23","author":"DW Ouyang","year":"2009","unstructured":"Ouyang DW, Shapiro DE, Lu M, Brogly SB, French AL, Leighty RM, et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS. 2009;23(18):2425\u201330.","journal-title":"AIDS"},{"issue":"9","key":"523_CR36","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/QAD.0b013e32835f1db0","volume":"27","author":"Z Shubber","year":"2013","unstructured":"Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Th\u00e9ry F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27(9):1403\u201312.","journal-title":"AIDS"},{"key":"523_CR37","volume-title":"Hepatotoxicity and liver-related mortality in women of child-bearing potential living with HIV and high CD4 counts initiating Efavirenz-Containing regimens","author":"D Bhattacharya","year":"2020","unstructured":"Bhattacharya D, Gupta A, Tierney C, Huang S, Peters MG, Chipato T, et al. Hepatotoxicity and liver-related mortality in women of child-bearing potential living with HIV and high CD4 counts initiating Efavirenz-Containing regimens. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America; 2020."},{"key":"523_CR38","first-page":"89","volume":"61","author":"A Avihingsanon","year":"2017","unstructured":"Avihingsanon A, Maek ANW, Gatechompol S, Sapsirisavat V, Thiansanguankul W, Sophonphan J, et al. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-na\u00efve and experienced HIV-1-infected thai adults. Int J Infect diseases: IJID : official publication Int Soc Infect Dis. 2017;61:89\u201396.","journal-title":"Int J Infect diseases: IJID : official publication Int Soc Infect Dis"},{"key":"523_CR39","doi-asserted-by":"crossref","unstructured":"Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE et al. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. Journal of acquired immune deficiency syndromes (1999). 2010;54(1):63\u201370.","DOI":"10.1097\/QAI.0b013e3181c6c65c"},{"issue":"11","key":"523_CR40","doi-asserted-by":"publisher","first-page":"F79","DOI":"10.1097\/00002030-199907300-00002","volume":"13","author":"F Garc\u00eda","year":"1999","unstructured":"Garc\u00eda F, Plana M, Vidal C, Cruceta A, O\u2019Brien WA, Pantaleo G, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS. 1999;13(11):F79\u201386.","journal-title":"AIDS"},{"issue":"8","key":"523_CR41","first-page":"148","volume":"62","author":"CDC","year":"2013","unstructured":"CDC. Impact of an innovative approach to prevent mother-to-child transmission of HIV\u2013Malawi, July 2011-September 2012. MMWR Morbidity and mortality weekly report. 2013;62(8):148\u201351.","journal-title":"MMWR Morbidity and mortality weekly report"},{"issue":"4","key":"523_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/QAD.0000000000000143","volume":"28","author":"L Tenthani","year":"2014","unstructured":"Tenthani L, Haas AD, Tweya H, Jahn A, van Oosterhout JJ, Chimbwandira F, et al. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women (\u2018option B+\u2019) in Malawi. AIDS. 2014;28(4):589\u201398.","journal-title":"AIDS"},{"issue":"4","key":"523_CR43","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3018(16)00008-4","volume":"3","author":"AD Haas","year":"2016","unstructured":"Haas AD, Tenthani L, Msukwa MT, Tal K, Jahn A, Gadabu OJ, et al. Retention in care during the first 3 years of antiretroviral therapy for women in Malawi\u2019s option B + programme: an observational cohort study. The lancet HIV. 2016;3(4):e175\u201382.","journal-title":"The lancet HIV"},{"issue":"11","key":"523_CR44","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/infdis\/jis553","volume":"206","author":"JY Chen","year":"2012","unstructured":"Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206(11):1695\u2013705.","journal-title":"J Infect Dis"},{"key":"523_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12884-016-0821-3","volume":"16","author":"T Moodley","year":"2016","unstructured":"Moodley T, Moodley D, Sebitloane M, Maharaj N, Sartorius B. Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. BMC Pregnancy Childbirth. 2016;16:35.","journal-title":"BMC Pregnancy Childbirth"},{"key":"523_CR46","doi-asserted-by":"crossref","unstructured":"Zash R, Souda S, Chen JY, Binda K, Dryden-Peterson S, Lockman S et al. Reassuring Birth Outcomes With Tenofovir\/Emtricitabine\/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana. Journal of acquired immune deficiency syndromes (1999). 2016;71(4):428 \u2013 36.","DOI":"10.1097\/QAI.0000000000000847"},{"issue":"2","key":"523_CR47","doi-asserted-by":"publisher","first-page":"e0192805","DOI":"10.1371\/journal.pone.0192805","volume":"13","author":"T Chetty","year":"2018","unstructured":"Chetty T, Thorne C, Coutsoudis A. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: results from a cohort study, 2010\u20132015. PLoS ONE. 2018;13(2):e0192805.","journal-title":"PLoS ONE"},{"issue":"1","key":"523_CR48","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2352-3018(16)30195-3","volume":"4","author":"OA Uthman","year":"2017","unstructured":"Uthman OA, Nachega JB, Anderson J, Kanters S, Mills EJ, Renaud F, et al. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. The lancet HIV. 2017;4(1):e21\u2013e30.","journal-title":"The lancet HIV"},{"key":"523_CR49","volume-title":"Pregnancy outcomes of women conceiving on antiretroviral therapy (ART) compared to those commenced on ART during pregnancy","author":"G Theron","year":"2020","unstructured":"Theron G, Brummel S, Fairlie L, Pinilla M, McCarthy K, Owor M, et al. Pregnancy outcomes of women conceiving on antiretroviral therapy (ART) compared to those commenced on ART during pregnancy. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America; 2020."}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00523-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-023-00523-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00523-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T09:07:10Z","timestamp":1686560830000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-023-00523-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["523"],"URL":"https:\/\/doi.org\/10.1186\/s12981-023-00523-1","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"22 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"37"}}